Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from
forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine
is more effective when given alone or together with dalteparin and/or capecitabine in
treating patients with pancreatic cancer.
PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots
in patients with pancreatic cancer receiving treatment with different combinations of
gemcitabine and capecitabine.
Phase:
Phase 3
Details
Lead Sponsor:
GERCOR - Multidisciplinary Oncology Cooperative Group Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)